Friday, European stocks ended mixed. The Stoxx Europe 600 Index added 0.16%. Germany's DAX 30 gained 0.35%, the U.K.'s FTSE 100 rose 0.63%, while France's CAC 40 was down 0.31%.
45% of STOXX 600 constituents traded higher Friday.
70% of the shares trade above their 20D MA vs 71% Thursday (above the 20D moving average).
49% of the shares trade above their 200D MA vs 48% Thursday (above the 20D moving average).
The Euro Stoxx 50 Volatility index eased 1.23pt to 25.58, a new 52w high.
SECTORS vs STOXX 600
3mths relative high: Chemicals, Utilities
3mths relative low: Retail, Real Estate
Europe Best 3 sectors
automobiles & parts, basic resources, technology
Europe worst 3 sectors
travel & leisure, insurance, energy
The 10yr Bund yield fell 2bps to -0.47% (below its 20D MA). The 2yr-10yr yield spread rose 0bp to -22bps (above its 20D MA).
GE 07:00: Jun PPI YoY, exp.: -2.2%
GE 07:00: Jun PPI MoM, exp.: -0.4%
EC 09:00: May Current Account, exp.: E10.2B
FR 14:00: 12-Mth BTF auction, exp.: -0.56%
FR 14:00: 3-Mth BTF auction, exp.: -0.56%
FR 14:00: 6-Mth BTF auction, exp.: -0.55%
In Asian trading hours, EUR/USD eased to 1.1419 and GBP/USD slid to 1.2525. USD/JPY rebounded to 107.38. This morning, government data showed that Japan's exports declined 26.2% on year in June (-24.7% expected) and imports slid 14.4% (-17.6% expected).
Spot gold retreated to $1,807 an ounce.
#UK - IRELAND#
GlaxoSmithKline, a pharmaceutical group, said it has signed a strategic collaboration agreement with biotechnology company CureVac for the development and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The company added: "GSK will make an equity investment in CureVac of £130m (E150m), representing close to a 10% stake, an upfront cash payment of £104m (E120m) and a one-time reimbursable payment of £26m (E30m) for manufacturing capacity reservation, upon certification of CureVac's commercial scale manufacturing facility currently under construction in Germany." From a chartist point of view, prices remain stuck within a mid term consolidation channel. The stock price is challenging its 20 and 50 DMAs. The RSI stands above 50% but lacks momentum. Above 1561p, the bias remains bullish. Next resistance thresholds are set at 1749p and 1857p in extension. A break below 1561p would call for a reversal down trend towards 1490p and 1415p.
Source: GAIN Capital, TradingView
Marks & Spencer, a retailing group, will announce hundreds of job cut this week due to the Covid-19, reported Sky News citing people familiar with the matter.
SSE, an energy company, was downgraded to "hold" from "buy" at Societe Generale.
Standard Life Aberdeen, an investment company, was downgraded to "underweight" from "equalweight" at Barclays.
Airbus, an aircraft manufacturer, said it has secured a 500 million pounds contract from the U.K. Ministry of Defence to build an additional satellite to support British military communications until at least 2040.
Natixis', a banking group, owner BPCE said it has no plan to acquire the remaining shares in the company, reported Bloomberg citing an emailed statement.
EssilorLuxottica, an eyewear conglomerate, announced that it has initiated legal proceedings before a Dutch district court to "obtain information from GrandVision. This is to assess the way GrandVision has managed the course of its business during the COVID-19 crisis, as well as the extent to which GrandVision has breached its obligations under the support agreement".
Teleperformance, an omnichannel company, was upgraded to "overweight" from "equalweight" at Morgan Stanley.
Intesa Sanpaolo, an Italian banking group, announced that it has raised is takeover offer for UBI Banca by adding an extra cash portion of 0.57 euro per share, representing about 652 million euros.
Julius Baer, a Swiss private bank, reported that 1H net income rose 43.2% on year to 491 million Swiss franc and operating income grew 8.9% to 1.85 billion Swiss franc. Also, assets under management fell 5.7% to 402 billion Swiss franc.
GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.